http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1578403-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_358a9e79a7e414d71b556d5b345503ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be2a46cf8c4cfe245af19d4e8cc2a8e1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 |
| filingDate | 2003-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd11e777b0f23e780a431f3131b0dab3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac50874a9d1b4ba9726ba1de8108bb83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_325e856f634db44aa555891169b96222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ad028f5a8448790cc53a58f0994b654 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da181b281a5644769330b23ebd719d47 |
| publicationDate | 2005-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1578403-A2 |
| titleOfInvention | Modified release compositions of milnacipran |
| abstract | A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (Optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia. |
| priorityDate | 2002-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1287.